Natixis’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.94M | Buy |
+6,970
| New | +$2.01M | 0.01% | 580 |
|
|
2024
Q3 | – | Sell |
-1,888
| Closed | -$516K | – | 972 |
|
|
2024
Q2 | $516K | Sell |
1,888
-98
| -5% | -$28.5K | ﹤0.01% | 613 |
|
|
2024
Q1 | $687K | Buy |
1,986
+65
| +3% | +$21.4K | ﹤0.01% | 582 |
|
|
2023
Q4 | $620K | Buy |
1,921
+540
| +39% | +$169K | ﹤0.01% | 589 |
|
|
2023
Q3 | $495K | Buy |
1,381
+98
| +8% | +$37.8K | ﹤0.01% | 607 |
|
|
2023
Q2 | $486K | Buy |
1,283
+587
| +84% | +$239K | ﹤0.01% | 644 |
|
|
2023
Q1 | $333K | Sell |
696
-299
| -30% | -$140K | ﹤0.01% | 679 |
|
|
2022
Q4 | $418K | Sell |
995
-420
| -30% | -$170K | ﹤0.01% | 738 |
|
|
2022
Q3 | $591K | Buy |
1,415
+379
| +37% | +$189K | ﹤0.01% | 865 |
|
|
2022
Q2 | $513K | Sell |
1,036
-52,404
| -98% | -$27.3M | ﹤0.01% | 938 |
|
|
2022
Q1 | $30.1M | Buy |
53,440
+36,886
| +223% | +$22.2M | 0.1% | 188 |
|
|
2021
Q4 | $12.5M | Buy |
16,554
+15,981
| +2,789% | +$12M | 0.04% | 335 |
|
|
2021
Q3 | $427K | Buy |
573
+70
| +14% | +$52.4K | ﹤0.01% | 1037 |
|
|
2021
Q2 | $324K | Sell |
503
-144,225
| -100% | -$87.8M | ﹤0.01% | 778 |
|
|
2021
Q1 | $82.7M | Buy |
144,728
+92,340
| +176% | +$54.7M | 0.27% | 81 |
|
|
2020
Q4 | $30.5M | Buy |
+52,388
| New | +$29.8M | 0.11% | 184 |
|
|
2020
Q3 | – | Sell |
-679
| Closed | -$307K | – | 766 |
|
|
2020
Q2 | $307K | Sell |
679
-21,517
| -97% | -$9.5M | ﹤0.01% | 662 |
|
|
2020
Q1 | $7.78M | Buy |
22,196
+6,177
| +39% | +$2.27M | 0.06% | 221 |
|
|
2019
Q4 | $5.92M | Sell |
16,019
-22,354
| -58% | -$7.88M | 0.04% | 374 |
|
|
2019
Q3 | $12.8M | Buy |
+38,373
| New | +$12.5M | 0.08% | 224 |
|
|
2019
Q2 | – | Sell |
-93,823
| Closed | -$28.5M | – | 763 |
|
|
2019
Q1 | $28.5M | Buy |
+93,823
| New | +$25.3M | 0.18% | 126 |
|
|
2018
Q3 | – | Sell |
-6,774
| Closed | -$1.96M | – | 822 |
|
|
2018
Q2 | $1.96M | Sell |
6,774
-5,221
| -44% | -$1.44M | 0.01% | 528 |
|
|
2018
Q1 | $3M | Buy |
11,995
+4,357
| +57% | +$1.11M | 0.02% | 454 |
|
|
2017
Q4 | $1.82M | Buy |
7,638
+1,249
| +20% | +$303K | 0.01% | 427 |
|
|
2017
Q3 | $1.42M | Buy |
+6,389
| New | +$1.44M | 0.01% | 470 |
|
|
2017
Q2 | – | Sell |
-4,028
| Closed | -$803K | – | 825 |
|
|
2017
Q1 | $803K | Buy |
+4,028
| New | +$776K | 0.01% | 425 |
|
Other funds holding BIO
VCM
VPM
AI
Natixis's BIO Position: Q1 2026 in Review
Natixis opened a new position in Bio-Rad Laboratories Class A (BIO) in Q1 2026: 6,970 shares worth $1.94M. The stake represents 0.01% of the portfolio and ranks #580 among its holdings. This is a return to the name: Natixis previously reported a position in BIO as recently as Q2 2024.
Natixis first reported a position in BIO in Q1 2017 and has held it in 26 quarters since. The position peaked at $82.7M in Q1 2021. 393 funds tracked by Wall St. Rank hold BIO as of Q1 2026.
- Natixis held 6,970 shares of Bio-Rad Laboratories Class A worth $1.94M as of Q1 2026.
- Bio-Rad Laboratories Class A was a new Natixis position in Q1 2026.
- Bio-Rad Laboratories Class A made up 0.01% of Natixis's portfolio in Q1 2026, its #580 holding.
- Natixis first reported a position in Bio-Rad Laboratories Class A in Q1 2017 and has held it in 26 quarters since.
- Natixis's Bio-Rad Laboratories Class A position peaked at $82.7M in Q1 2021.
- 393 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.
Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.